Cover Image

In-House Radio-Labelling Of 131i-Rituximab In Threatment Of Cd20+ B-Cell Non-Hodgkin’s Lymphoma: A Pioneer Experience In Malaysia

Background Radioimmunotherapy (RIT) is an established treatment modality in Non-Hodgkin’s lymphoma (NHL). The only two commercially available RITs - 90Y-ibritumomab tiuxetan (Zevalin®) is expensive and 131I-tositumomab has been discontinued from commercial production. In resource limited environm...

Full description

Saved in:
Bibliographic Details
Main Authors: Kuan, Jew Win, Law, Chiong Soon, Wong, Xiang Qi, Ko, Ching Tiong, Awang, Zool Hilmi, Chew, Lee Ping, Chang, Kian Meng
Format: Conference or Workshop Item
Language:English
Published: 2016
Subjects:
RZ Other systems of medicine
Online Access:http://ir.unimas.my/id/eprint/12287/3/IN-HOUSE%20RADIO-LABELLING%20OF%20131I-RITUXIMAB%20IN%20THREATMENT%20OF%20CD20%2B%20B-CELL%20NON-HODGKIN%E2%80%99S%20LYMPHOMA.pdf
http://ir.unimas.my/id/eprint/12287/
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://ir.unimas.my/id/eprint/12287/3/IN-HOUSE%20RADIO-LABELLING%20OF%20131I-RITUXIMAB%20IN%20THREATMENT%20OF%20CD20%2B%20B-CELL%20NON-HODGKIN%E2%80%99S%20LYMPHOMA.pdf
http://ir.unimas.my/id/eprint/12287/

Similar Items